

## Items supported by the Samaritan Fund

(a) [Non-drug Items supported by the Fund](#)

(b) [Other items supported by the Samaritan Fund Mechanism](#)

(c) [Self-financed Drugs supported by the Samaritan Fund \(SF\) and Community Care Fund \(CCF\) Medical Assistance Programme \(First Phase Programme\) \(for specified self-financed cancer drugs\)](#)

### (a) Non-drug Items supported by the Fund

1. Percutaneous Transluminal Coronary Angioplasty (PTCA) and other consumables for interventional cardiology
2. Cardiac Pacemakers
3. Myoelectric Prosthesis
4. Custom-made Prosthesis
5. Appliances for prosthetic and orthotic services, physiotherapy and occupational therapy services (e.g. prosthesis)
6. Home use equipment and appliances (e.g. wheelchair, replacement of external speech processor for patients done with cochlear implant)
7. Gamma knife surgery
8. Harvesting of marrow in a foreign country for marrow transplant

The Fund will only support the model which can meet the basic medical needs of the patients.

### (b) Other items supported by the Samaritan Fund Mechanism

1. Positron Emission Tomography (PET) service

### (c) Drugs supported by the Samaritan Fund

The following specific self-financed drugs are supported by the Samaritan Fund:

Item	Drug	Types of diseases	Clinical indications
1	Abatacept	Rheumatology	Rheumatoid arthritis
2a	Adalimumab	Dermatology	Severe psoriasis
2b		Ophthalmology	Non-infectious intermediate, posterior and panuveitis
2c			Paediatric chronic non-infectious anterior uveitis
2d		Rheumatology	Ankylosing spondylitis
2e			Juvenile idiopathic arthritis
2f			Psoriatic arthritis
2g			Rheumatoid arthritis

Item	Drug	Types of diseases	Clinical indications
3	Afatinib	Oncology	Non-small cell lung cancer with activating EGFR mutation (first-line treatment)
4	Alectinib <sup>#</sup>	Oncology	ALK+ve non-small cell lung cancer (NSCLC)
5a	Azacitidine	Haematology	Acute myeloid leukaemia (AML)
5b			Chronic myelomonocytic leukaemia (CMML)
5c			Myelodysplastic syndromes (MDS)
6	Baricitinib	Rheumatology	Rheumatoid arthritis
7	Belimumab	Rheumatology	Systemic lupus erythematosus (SLE)
8	Benralizumab	Respiratory Medicine	Severe refractory eosinophilic asthma (add-on treatment)
9	Bortezomib	Haematology	Multiple myeloma (MM)
10	Canakinumab	Others	Cryopyrin-associated periodic syndromes
11	Carfilzomib	Haematology	Multiple myeloma (MM)
12	Ceritinib <sup>#</sup>	Oncology	ALK+ve non-small cell lung cancer (NSCLC)
13a	Certolizumab Pegol	Rheumatology	Ankylosing spondylitis
13b			Psoriatic arthritis
13c			Rheumatoid arthritis
14	Cetuximab	Oncology	RAS wild-type colorectal cancer
15a	Crizotinib <sup>#</sup>	Oncology	ALK+ve non-small cell lung cancer (NSCLC)
15b			ROS1-positive non-small cell lung cancer (NSCLC)
16a	Dasatinib	Haematology	Imatinib-resistant chronic myeloid leukaemia (CML)
16b			Imatinib-resistant philadelphia or BCR/ABL positive acute lymphoblastic leukaemia (ALL)
16c			Newly diagnosed chronic myeloid leukaemia (CML) in chronic phase
16d			Nilotinib-resistant chronic myeloid leukaemia (CML)
17	<b>Specific ultra-expensive drug</b> (The patient must be a permanent resident of the Hong Kong Special Administrative Region according to the Immigration Ordinance)		
	Eculizumab	Haematology	Paroxysmal nocturnal haemoglobinuria (PNH)

Item	Drug	Types of diseases	Clinical indications
18a	Eltrombopag	Haematology	Chronic immune thrombocytopenia (for post-splenectomised patients; or non-splenectomised patients in whom splenectomy is contraindicated)
18b			Severe aplastic anaemia (SAA) <sup>#^</sup>
19a	Etanercept	Dermatology	Severe psoriasis
19b		Rheumatology	Ankylosing spondylitis
19c			Juvenile idiopathic arthritis
19d			Psoriatic arthritis
19e			Rheumatoid arthritis
20	Gefitinib	Oncology	Non-small cell lung cancer with activating EGFR mutation (first-line or second-line treatment)
21a	Golimumab	Rheumatology	Ankylosing spondylitis
21b			Psoriatic arthritis
21c			Rheumatoid arthritis
22	Growth Hormone	Endocrinology	Dwarfism
23	Guselkumab	Dermatology	Severe psoriasis
24a	Ibrutinib <sup>#</sup>	Haematology	Relapsed or refractory mantle cell lymphoma (MCL)
24b			Relapsed / refractory chronic lymphocytic leukaemia (CLL)
25	Imatinib	Oncology	Gastrointestinal stromal tumour
26a	Infliximab	Dermatology	Severe psoriasis
26b		Gastroenterology	Severe ulcerative colitis
26c		Rheumatology	Ankylosing spondylitis
26d			Psoriatic arthritis
26e			Rheumatoid arthritis
27	Interferon	Others	Chronic granulomatous disease
28	Lenalidomide <sup>#</sup>	Haematology	Multiple myeloma (MM)
29	Mepolizumab	Respiratory Medicine	Severe refractory eosinophilic asthma (add-on treatment)
30	Midostaurin <sup>#</sup>	Haematology	Acute myeloid leukaemia (AML)

Item	Drug	Types of diseases	Clinical indications
31	Natalizumab	Neurology	Relapsing-remitting multiple sclerosis (RRMS)
32a	Nilotinib	Haematology	Dasatinib-resistant chronic myeloid leukaemia (CML)
32b			Imatinib-resistant chronic myeloid leukaemia (CML)
32c			Newly diagnosed chronic myeloid leukaemia (CML) in chronic phase
33	Nintedanib (Ofev) <sup>#</sup>	Respiratory Medicine	Idiopathic pulmonary fibrosis (IPF)
34	Obinutuzumab	Haematology	Follicular lymphoma
35	Omalizumab	Respiratory Medicine	Severe persistent confirmed allergic IgE mediated asthma
36	Panitumumab	Oncology	RAS wild-type colorectal cancer
37	Pertuzumab <sup>^</sup>	Oncology	HER2 positive breast cancer
	Trastuzumab		
38a	Plerixafor	Haematology	Multiple myeloma (MM)
38b			Non-Hodgkin's lymphoma (NHL)
39	Pomalidomide <sup>#^</sup>	Haematology	Multiple myeloma (MM)
40a	Ponatinib <sup>^</sup>	Haematology	Acute lymphoblastic leukaemia (ALL)
40b			Chronic myeloid leukaemia (CML)
41	Risankizumab <sup>^</sup>	Dermatology	Severe psoriasis
42a	Rituximab	Haematology	Maintenance therapy for relapsed follicular lymphoma (RFL)
42b			Previously-untreated and relapsed / refractory chronic lymphocytic leukaemia (CLL)
42c		Oncology	Malignant lymphoma (ML)
42d		Rheumatology	Refractory rheumatoid arthritis (RRA)
42e			Severe, active non-life-threatening granulomatosis with polyangiitis/microscopic polyangiitis
43	Ruxolitinib <sup>#</sup>	Haematology	Myelofibrosis-related splenomegaly or symptoms
44	Sarilumab	Rheumatology	Rheumatoid arthritis
45a	Secukinumab	Dermatology	Severe psoriasis

Item	Drug	Types of diseases	Clinical indications
45b		Rheumatology	Ankylosing spondylitis
45c			Psoriatic arthritis
46	Sorafenib~	Oncology	Hepatocellular carcinoma (HCC)~
47	Temozolomide	Oncology	Recurrent high grade glioma
48a	Tocilizumab	Rheumatology	Systemic juvenile idiopathic arthritis (JIA)
48b			Juvenile idiopathic arthritis (JIA)
48c			Rheumatoid arthritis
48d			Refractory giant cell arteritis
49	Tofacitinib	Rheumatology	Rheumatoid arthritis
			Psoriatic arthritis^
50	Tolvaptan (Jinarc)	Nephrology	Autosomal dominant polycystic kidney disease (ADPKD)
51a	Trastuzumab	Oncology	HER2 over-expressed metastatic breast cancer (MBC)
51b			HER2 positive early breast cancer (EBC)
52	Trastuzumab emtansine (T-DM1)^	Oncology	HER2 positive early breast cancer (EBC)
53a	Ustekinumab	Dermatology	Severe psoriasis
53b		Rheumatology	Psoriatic arthritis
54	Vedolizumab	Gastroenterology	Severe ulcerative colitis

Remarks:

- ^ With effect from 22 May 2021.
- ~ Sorafenib is repositioned from CCF Medical Assistance Programme (First Phase Programme) to SF with effect from 29 December 2020. New applications and renewal applications approved on or after the effective date will be subsidized by SF. For applications already approved before the effective date, CCF subsidy will be provided until end of treatment of the applications.
- # The concerned drugs are under Capping Programmes where free drugs are subsequently provided through designated community pharmacies. For details, please refer to the [\[Information Sheet\]](#).

**Self-financed Drugs supported by the Samaritan Fund (SF) and Community Care Fund (CCF) Medical Assistance Programme (First Phase Programme) (for specified self-financed cancer drugs)**

Types of Diseases	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
Haematology	Acute lymphoblastic leukaemia	Dasatinib, Ponatinib <sup>^</sup>	✓	
		Inotuzumab Ozogamicin		✓
	Acute myeloid leukaemia	Midostaurin <sup>#</sup>	✓	
	Chronic immune thrombocytopenia	Eltrombopag	✓	
	Chronic lymphocytic leukaemia	Ibrutinib <sup>#</sup> , Rituximab	✓	
		Bendamustine, Obinutuzumab		✓
	Chronic myeloid leukaemia	Dasatinib, Nilotinib, Ponatinib <sup>^</sup>	✓	
	Follicular lymphoma	Obinutuzumab, Rituximab	✓	
	Mantle cell lymphoma	Ibrutinib <sup>#</sup>	✓	
	Multiple myeloma	Bortezomib, Carfilzomib, Lenalidomide <sup>**</sup> , Pomalidomide <sup>#^</sup>	✓	
		Ixazomib <sup>#</sup> & Lenalidomide <sup>**</sup>		✓
	Multiple myeloma / Non-Hodgkin's lymphoma	Plerixafor	✓	
	Myelodysplastic syndromes / chronic myelomonocytic leukaemia / acute myeloid leukaemia	Azacitidine	✓	
	Myelofibrosis-related splenomegaly or	Ruxolitinib <sup>#</sup>	✓	

Types of Diseases	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	symptoms			
	Paroxysmal nocturnal haemoglobinuria	Eculizumab	✓	
	Severe aplastic anaemia	Eltrombopag <sup>#^</sup>	✓	
	CD30+ Hodgkin lymphoma / Systemic anaplastic large cell lymphoma / CD30+ cutaneous T-cell lymphoma	Brentuximab Vedotin		✓
Respiratory Medicine	Idiopathic pulmonary fibrosis	Nintedanib (Ofev) <sup>#</sup>	✓	
	Severe persistent confirmed allergic IgE mediated asthma	Omalizumab	✓	
	Severe refractory eosinophilic asthma	Mepolizumab, Benralizumab	✓	
Rheumatology	Systemic juvenile idiopathic arthritis	Tocilizumab	✓	
	Ankylosing spondylitis	Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab, Secukinumab	✓	
	Juvenile idiopathic arthritis	Adalimumab, Etanercept, Tocilizumab	✓	
	Psoriatic arthritis	Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab, Secukinumab, Tofacitinib <sup>^</sup> Ustekinumab	✓	

Types of Diseases	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Rheumatoid arthritis	Abatacept, Adalimumab, Baricitinib, Certolizumab Pegol, Etanercept, Golimumab, Infliximab, Sarilumab, Tocilizumab, Tofacitinib	✓	
	Refractory rheumatoid arthritis	Rituximab	✓	
	Refractory giant cell arteritis	Tocilizumab	✓	
	Severe, active non-life-threatening granulomatosis with polyangiitis / microscopic polyangiitis	Rituximab	✓	
	Systemic lupus erythematosus (SLE)	Belimumab	✓	
Nephrology	Autosomal dominant polycystic kidney disease	Tolvaptan (Jinarc)	✓	
Neurology	Relapsing remitting multiple sclerosis	Natalizumab	✓	
Oncology	Bladder cancer	Pembrolizumab <sup>^</sup>		✓
	Breast cancer	Pertuzumab <sup>*^</sup> and Trastuzumab, Trastuzumab emtansine <sup>*^</sup>	✓	
		Abemaciclib <sup>#</sup> , Everolimus <sup>#</sup> , Lapatinib, Palbociclib <sup>#</sup> , Pertuzumab <sup>*</sup> , Ribociclib <sup>#</sup> , Trastuzumab		✓



Types of Diseases	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
		emtansine*		
	Colorectal cancer	Cetuximab, Panitumumab	✓	
		Bevacizumab		✓
	Gastric carcinoma	Trastuzumab		✓
	Gastrointestinal tumour	Sunitinib		✓
	Gastrointestinal stromal tumour	Imatinib	✓	
	Recurrent high grade glioma	Temozolomide	✓	
	Liver cancer	Sorafenib	✓~	
		Lenvatinib#		✓
	Lung cancer	Ceritinib*#,	✓	✓
		Afatinib, Alectinib*#, Crizotinib#, Gefitinib	✓	
		Alectinib*#, Atezolizumab, Brigatinib#, Durvalumab, Nivolumab, Osimertinib#, Pembrolizumab		✓
	Malignant lymphoma	Rituximab	✓	
	Ovarian cancer	Pegylated liposomal Doxorubicin		✓
	Epithelial ovarian / fallopian tube / primary peritoneal cancer	Bevacizumab, Olaparib#^		✓

Types of Diseases	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Prostate cancer	Abiraterone <sup>#</sup> , Enzalutamide <sup>#</sup>		✓
	Renal cell carcinoma	Axitinib <sup>#</sup> , Sunitinib, Pazopanib		✓
	Skin cancer	Dabrafenib <sup>#</sup> and Trametinib <sup>#</sup> , Nivolumab, Vemurafenib		✓
Gastroenterology	Severe ulcerative colitis	Infliximab, Vedolizumab	✓	
Ophthalmology	Non-infectious intermediate, posterior and panuveitis	Adalimumab	✓	
	Paediatric chronic non-infectious anterior uveitis	Adalimumab	✓	
Endocrinology	Dwarfism	Growth Hormone	✓	
Dermatology	Severe psoriasis	Adalimumab, Etanercept, Guselkumab, Infliximab, Risankizumab <sup>^</sup> , Secukinumab, Ustekinumab	✓	
Others	Chronic granulomatous disease	Interferon	✓	
	Cryopyrin-associated periodic syndromes	Canakinumab	✓	

Remarks:

- ^ With effect from 22 May 2021.
- \* The designated clinical indications of the same drug supported by different funds are different. Please consult your case doctor for details.
- ~ Sorafenib is repositioned from CCF Medical Assistance Programme (First Phase Programme) to SF with effect from 29 December 2020. New applications and renewal applications approved on or after the effective date will be subsidized by SF. For applications already approved before the effective date, CCF subsidy will be provided until end of treatment of the applications.
- # The concerned drugs are under Capping Programmes where free drugs are subsequently provided through designated community pharmacies. For details, please refer to the [\[Information Sheet\]](#).

Patients who have financial difficulties may apply for assistance from the Fund. Eligible applicants may be given full or partial assistance of the treatment cost, depending on their financial situation

For details of drugs covered by the CCF Medical Assistance Programmes, namely the First Phase Programme and the “Subsidy for Eligible Patients to Purchase Ultra-expensive Drugs (Including Those for Treating Uncommon Disorders)”, please refer to the [CCF Medical Assistance Programmes](#) web page in the Hospital Authority Website.